Egypt’s Cardiovascular diseases drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
In Egypt, cardiovascular disease (CVD) has been the leading cause of premature death since the 1990s. It is the most populous of the Middle East and North American countries and recent studies revealed higher CAD mortality rates in this region. In 2017, CVD accounted for 46.2% of the overall mortality in Egypt. Given the aging of the population and the success in prolonging the survival of those with coronary events, heart failure (HF) poses an important and growing public health burden.
Recent studies expressed that ACS patients in Egypt are relatively young (mean age 57 years) compared with patients living in the West (mean age 66 years). In line with the Cardio Risk study done across Egypt, central obesity, diabetes, and hypertension were more prevalent in women with ACS and were acknowledged as major risk factors for ACS. With these statistics, the market for the disease is likely to grow in demand in the forecast period.
Egypt’s epidemiological profile, characterized by a high chronic disease burden, will drive prescription medicine expenditure over the coming years. Rapid population growth and a gradually aging population represent potential for pharmaceutical firms to expand, with the emergence of diabetes, hypertension, and cardiovascular diseases driving the growth of higher value prescription medicines.
The disease burden of Cardiovascular has consistently topped the list of most death-causing diseases in Egypt and is likely to grow in the future. Ischemic heart disease has consistently remained on top of the table for Egypt and the deaths caused by it have seen a rise of 26.9% from 2009 to 2019. It is also the no. one cause for DALYs in Egypt. Mortality caused by Hypertensive heart diseases has seen a rise of 24.4.% from 2009 to 2019.
Further, data indicate that the elder population has a higher prevalence of CAD risk factors. Given that the geriatric population of Egypt is expected to expand by more than twice its present size, the risk of cardiovascular disease will also increase. Such a rise in the burden of the disease will drive the cardiovascular disease drug market in Egypt.
Other initiatives such as 100 million healthy Lives, launched in Egypt will drive the NCD pharmaceuticals market due to increased awareness, diagnosis, and treatment among the population.
This indicates that the pharmaceutical market of Egypt is likely to encourage local players more than international penetration in the near future.